Research Articles | Page 3 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management Aug 2020 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond May 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Mar 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia Jul 2023 Annals of Hematology Aplastic Anemia
Quality of life after immune suppressive therapy in aplastic anemia Apr 2024 Annals of Hematology Aplastic Anemia
Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series Jan 2021 Annals of Hematology Aplastic Anemia
Evolving therapies for lower-risk myelodysplastic syndromes Apr 2020 Annals of Hematology Myelodysplastic Syndromes (MDS)
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry May 2020 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Oct 2023 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)